TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Argenica Therapeutics Ltd ( (AU:AGN) ) is now available.
Argenica Therapeutics has completed its first trial in acute ischaemic stroke patients, focusing on the safety of its lead product, ARG-007. Despite a fall in share price due to the trial’s top line results, the company remains optimistic about ARG-007’s potential, particularly in specific patient subgroups. The company has secured $1.5 million in grant funding to support further trials and continues to explore ARG-007’s applications in other brain injury indications. Argenica is also strengthening its team to navigate regulatory approvals and expand its clinical trials globally.
The most recent analyst rating on (AU:AGN) stock is a Buy with a A$0.63 price target. To see the full list of analyst forecasts on Argenica Therapeutics Ltd stock, see the AU:AGN Stock Forecast page.
More about Argenica Therapeutics Ltd
Argenica Therapeutics Limited is a neurology development company focused on developing treatments for acute brain injuries. Its primary product, ARG-007, is aimed at treating conditions such as acute ischaemic stroke, traumatic brain injury, and hypoxic-ischaemic encephalopathy in newborns. The company is actively engaged in clinical trials and research to validate its therapeutic offerings and expand its market presence.
Average Trading Volume: 586,727
Technical Sentiment Signal: Sell
For a thorough assessment of AGN stock, go to TipRanks’ Stock Analysis page.